Akums Drugs and Pharmaceuticals
MAINBOARD
Listed
Price Band
₹646 - ₹679
Lot Size
22 Shares
Issue Size
₹680.00 Cr
Fresh Issue
₹476.00 Cr
OFS
₹204.00 Cr
Registrar
Link Intime India Private Limited
AI Sentiment Score
Listing Price
₹725.00
vs Issue: ₹679 (+6.77%)
📅 IPO Timeline
✓
Open
Jul 30, 2024
✓
Close
Aug 1, 2024
✓
Allotment
Aug 2, 2024
✓
Refund
Aug 5, 2024
✓
Demat
Aug 5, 2024
✓
Listing
Aug 6, 2024
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
Akums Drugs and Pharmaceuticals displays an established operational footprint with expanding revenue streams (6.0% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (6.0% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 14.9%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 3,655.00 Cr | Rs 4,178.00 Cr | Rs 4,118.00 Cr | Rs 4,359.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 98.00 Cr | Rs 1.00 Cr | Rs 344.00 Cr | Rs 256.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 294.00 Cr | Rs 123.00 Cr | Rs 465.00 Cr | Rs 522.00 Cr |
| Borrowings (₹ Cr) | Rs 619.00 Cr | Rs 565.00 Cr | Rs 88.00 Cr | Rs 157.00 Cr |
| Total Assets (₹ Cr) | Rs 3,241.00 Cr | Rs 3,504.00 Cr | Rs 4,095.00 Cr | Rs 5,429.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 14.90% | 14.90% | 14.90% | 14.90% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
42.1x
Industry P/E
48.4x
Debt/Equity
0.05
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 48.4x
IPO 42.1x
0x (Deep Value)
65x (High Multiple)
📋 Live Subscription Status
QIB
90.09x
NII
47.43x
Retail
21.30x
Total
63.56x
🎯 Retail Allotment Probability
4.7% Odds
1 in 21.3 chance (~4.7% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:43 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹680.0 Cr
Issue Size
Fresh (70%)
OFS (30%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.